CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Non-coding RNA Research, published by KEAI PUBLISHING LTD, is a leading open-access journal dedicated to advancing the field of non-coding RNA, a critical component in the landscape of molecular biology and genetics. Established in 2016, this journal aims to provide a platform for the dissemination of high-quality research focusing on the roles, mechanisms, and therapeutic potentials of non-coding RNAs in various biological processes and diseases. With impressive Scopus rankings placing it in the top quartile for both Biochemistry and Medical Biochemistry, as well as notable standings in Genetics and Molecular Biology, Non-coding RNA Research continues to attract contributions from globally recognized experts. The journal's commitment to open access ensures broad visibility and engagement with cutting-edge discoveries, thereby fostering an inclusive scientific dialogue that enhances understanding and innovation in this rapidly evolving field. For researchers and scholars, the opportunity to publish in a Q1 ranked journal not only validates their work but also enhances its impact, making Non-coding RNA Research an indispensable resource for anyone interested in the intricate workings of non-coding RNA.

ACTA BIOCHIMICA POLONICA (ISSN: 0001-527X, E-ISSN: 1734-154X) is a distinguished journal published by the ACTA BIOCHIMICA POLONICA in Poland, with a rich history dating back to 1955. As a prominent platform for disseminating research, it currently holds a Category Quartile of Q3 in the fields of Biochemistry, Genetics, and Molecular Biology, reflecting its commitment to advancing knowledge in these critical areas. This journal is indexed in Scopus, ranking 124 out of 221, placing it in the 44th percentile among general biochemistry, genetics, and molecular biology journals. Although it does not operate under an open-access model, ACTA BIOCHIMICA POLONICA remains a vital resource for researchers, professionals, and students seeking to delve into the latest developments and discoveries in biochemistry and molecular biology. Its strategic focus on contemporary topics ensures that it plays an essential role in shaping future scientific inquiries and fostering collaboration across various disciplines.

BIOFACTORS, an esteemed journal published by Wiley, serves as a pivotal resource in the fields of Biochemistry, Clinical Biochemistry, and Molecular Medicine. With ISSN 0951-6433 and E-ISSN 1872-8081, the journal has established its reputation since its inception in 1988, showcasing a rich history of scientific inquiry and innovation. Recognized for its high academic standards, it currently holds a Q1 ranking in key categories, including Biochemistry and Medicine (miscellaneous), and ranks in the top 10% for Clinical Biochemistry according to Scopus metrics, reflecting its impact and influence in the scientific community. Although it does not offer Open Access, BIOFACTORS provides researchers the opportunity to publish and disseminate high-quality studies that advance our understanding of biological factors and their clinical implications. The journal actively encourages contributions that bridge the gap between laboratory findings and clinical applications, making it a vital platform for both seasoned researchers and emerging scholars in the life sciences.

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.